![European Crohn´s and Colitis Organisation - ECCO - P405 Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn's Disease – preliminary results from European Crohn´s and Colitis Organisation - ECCO - P405 Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn's Disease – preliminary results from](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC22/abstracts/0000000370/0000607590/Images/table2logisticregressionofpnr.jpg)
European Crohn´s and Colitis Organisation - ECCO - P405 Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn's Disease – preliminary results from
Driven Birgitte Holdt email address & phone number | ECCO Shoes HR Business Partner contact information - RocketReach
![Trainging transformation: ECCO takes training to the next level with ASA University | Supply House Times Trainging transformation: ECCO takes training to the next level with ASA University | Supply House Times](https://www.supplyht.com/ext/resources/Issues/2023/05-May/SHT-0523-ASA-News3-Feat-Slide1-1170x658.jpg?t=1683555180&width=696)